May 7 (Reuters) - Ultimovacs ASA ULTI.OL :
* NEGATIVE INITIUM RESULTS HAVE HAD IMPORTANT CONSEQUENCES FOR COMPANY
* IMPLEMENTED CASH PRESERVATION INITIATIVES EXTENDS ANTICIPATED FINANCIAL RUNWAY TO Q4 OF
2025,
BEYOND ANTICIPATED TOPLINE READOUT OF FOCUS AND DOVACC TRIALS
* WE ARE LOOKING FORWARD TO FORTHCOMING RESULTS FROM NEXT PHASE II TRIAL FOR UV1, FOCUS IN
HEAD
AND NECK CANCER, EXPECTED IN Q3 - CEO
* BASED ON CURRENT PLANS AND FORECAST, CASH BURN RATE IS ESTIMATED TO BE APPROXIMATELY 15
MNOK PER
QUARTER TOWARDS END OF 2025
Source text for Eikon: ID:nGNE5vvSSp
Further company coverage: ULTI.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))